LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT): Nasdaq/NYSE listing notice — Lixte Biotechnology fails Nasdaq equity minimum; plans appeal to avoid delisting

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Failed to meet Nasdaq's $2.5M stockholders' equity requirement by Feb 18, 2025 extension deadline.
Received Staff determination letter on Feb 19, 2025; intends to appeal and request a hearing.
Appeal will automatically stay delisting of common stock (LIXT) and warrants (LIXTW) pending Panel decision.
Nasdaq Hearings Panel may grant additional extension until Aug 18, 2025 to regain compliance.
Company had previously submitted a compliance plan in Oct 2024 after initial Aug 2024 deficiency notice.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

LIXTE BIOTECHNOLOGY HOLDINGS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)

Exact text from the filing

om the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) on August 19, 2024 indicating that the Company was not in compliance with the minimum stockholders’ equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b) (the “Stockholders’ Equity Requirement”). On October 3, 2024, the Company submitted a plan to the Staff to regain compliance with the Stockholders’ Equity Requirement, which outlined the Company’s proposed initiatives to regain compliance by raising equity capital through various registered

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

LIXTE BIOTECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-25-007865

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.